JP7862297B2 - 癌の治療 - Google Patents
癌の治療Info
- Publication number
- JP7862297B2 JP7862297B2 JP2022513249A JP2022513249A JP7862297B2 JP 7862297 B2 JP7862297 B2 JP 7862297B2 JP 2022513249 A JP2022513249 A JP 2022513249A JP 2022513249 A JP2022513249 A JP 2022513249A JP 7862297 B2 JP7862297 B2 JP 7862297B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- cancer
- tumor
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019903263 | 2019-09-04 | ||
| AU2019903263A AU2019903263A0 (en) | 2019-09-04 | Cancer treatment | |
| AU2019904863A AU2019904863A0 (en) | 2019-12-20 | Cancer treatment (2) | |
| AU2019904863 | 2019-12-20 | ||
| PCT/AU2020/050936 WO2021042174A1 (en) | 2019-09-04 | 2020-09-04 | Cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026078263A Division JP2026129928A (ja) | 2019-09-04 | 2026-05-07 | 癌の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546807A JP2022546807A (ja) | 2022-11-09 |
| JP2022546807A5 JP2022546807A5 (cg-RX-API-DMAC7.html) | 2023-09-11 |
| JP7862297B2 true JP7862297B2 (ja) | 2026-05-19 |
Family
ID=74851931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513249A Active JP7862297B2 (ja) | 2019-09-04 | 2020-09-04 | 癌の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220347146A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4025203A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7862297B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020343725B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021042174A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2811957C (en) | 2010-09-22 | 2019-04-16 | The University Of Melbourne | Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents |
| IL275360B2 (en) | 2017-12-21 | 2023-10-01 | Axelia Oncology Pty Ltd | Optimal compounds |
| NZ783377A (en) | 2019-06-26 | 2026-03-27 | Ena Respiratory Pty Ltd | Pegylated novel molecules for agonising tlr2 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008529978A (ja) | 2005-02-08 | 2008-08-07 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | 免疫原性分子 |
| JP2012526092A (ja) | 2009-05-08 | 2012-10-25 | サイオクサス セラピューティクス リミティド | 多価アジュバントディスプレイ |
| JP2013537892A (ja) | 2010-09-22 | 2013-10-07 | ザ ユニバーシティー オブ メルボルン | 新規な免疫賦活法 |
| JP2014528955A (ja) | 2011-10-06 | 2014-10-30 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用 |
| WO2016037240A1 (en) | 2014-09-12 | 2016-03-17 | The University Of Melbourne | Immunological reagent |
| WO2018176099A1 (en) | 2017-03-31 | 2018-10-04 | Ena Therapeutics Pty Ltd | Treatment of respiratory infection with a tlr2 agonist |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3328418A1 (en) * | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| IL275360B2 (en) * | 2017-12-21 | 2023-10-01 | Axelia Oncology Pty Ltd | Optimal compounds |
| JP2022546806A (ja) * | 2019-09-04 | 2022-11-09 | アクセリア オンコロジー ピーティーワイ リミテッド | 癌免疫療法 |
-
2020
- 2020-09-04 WO PCT/AU2020/050936 patent/WO2021042174A1/en not_active Ceased
- 2020-09-04 US US17/640,714 patent/US20220347146A1/en active Pending
- 2020-09-04 JP JP2022513249A patent/JP7862297B2/ja active Active
- 2020-09-04 EP EP20859699.9A patent/EP4025203A4/en active Pending
- 2020-09-04 AU AU2020343725A patent/AU2020343725B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008529978A (ja) | 2005-02-08 | 2008-08-07 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | 免疫原性分子 |
| JP2012526092A (ja) | 2009-05-08 | 2012-10-25 | サイオクサス セラピューティクス リミティド | 多価アジュバントディスプレイ |
| JP2013537892A (ja) | 2010-09-22 | 2013-10-07 | ザ ユニバーシティー オブ メルボルン | 新規な免疫賦活法 |
| JP2014528955A (ja) | 2011-10-06 | 2014-10-30 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用 |
| WO2016037240A1 (en) | 2014-09-12 | 2016-03-17 | The University Of Melbourne | Immunological reagent |
| WO2018176099A1 (en) | 2017-03-31 | 2018-10-04 | Ena Therapeutics Pty Ltd | Treatment of respiratory infection with a tlr2 agonist |
Non-Patent Citations (2)
| Title |
|---|
| PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8+T cell responses,Biomaterials,2017年,vol.137,pp.61-72 |
| Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines,J. Med. Chem.,2019年08月16日,63,pp.2282-2291,DOI: 10.1021/acs.jmedchem.9b01044 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4025203A1 (en) | 2022-07-13 |
| US20220347146A1 (en) | 2022-11-03 |
| EP4025203A4 (en) | 2023-12-20 |
| AU2020343725A1 (en) | 2022-03-24 |
| JP2022546807A (ja) | 2022-11-09 |
| AU2020343725B2 (en) | 2026-07-16 |
| WO2021042174A1 (en) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100248030B1 (ko) | 시토킨 조절제 및 시토킨 농도 변화에 관련된 병변 및 질환에 있어서 그의 용도 | |
| US20240173309A1 (en) | Lipidated peptide inhibitors of interleukin-23 receptor | |
| JP4896728B2 (ja) | ブラジキニンb1受容体の拮抗薬 | |
| US10413614B2 (en) | Conjugates for protection from nephrotoxic active substances | |
| CN121371186A (zh) | 癌症免疫疗法 | |
| US20220347146A1 (en) | Cancer treatment | |
| JP2024036660A (ja) | ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン10薬剤 | |
| JP2026082831A (ja) | 修飾ペプチドおよび関連する使用方法 | |
| JP6913130B2 (ja) | 抗炎症性トリペプチド | |
| US20090264345A1 (en) | Macrocyclic peptides and methods for making and using them | |
| EP2010203A2 (en) | Macrocyclic peptides and methods for making and using them | |
| US20230372551A1 (en) | Radiolabeled ligands for targeted pet/spect imaging and methods of their use | |
| US20240252693A1 (en) | Folate receptor-targeted radiotherapeutic agents and their use | |
| US10189875B2 (en) | Anti-cancer peptide and use thereof | |
| MXPA04011502A (es) | Compuestos capaces de bloquear la respueta a sustancias quimicas o estimulos termicos o mediadores de la inflamacion de los nociceptores, un metodo para su obtencion y composiciones que los contienen. | |
| AU2017290096A1 (en) | Novel cyclic peptides and uses thereof | |
| KR102499473B1 (ko) | 여성 성기능장애를 치료하기 위한 신규한 펩타이드군 | |
| US20250121078A1 (en) | Peptide drug conjugates and their uses | |
| WO2022246141A2 (en) | Peptide drug conjugates specific to fibronectin isotypes for cancer therapy | |
| BR112018001207B1 (pt) | Uso de um peptídeo no tratamento ou na prevenção de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230901 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230901 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240910 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20241211 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250311 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250611 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250910 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260407 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260507 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7862297 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |